company background image
NURO

NeuroMetrix NasdaqCM:NURO Stock Report

Last Price

US$3.61

Market Cap

US$25.3m

7D

11.4%

1Y

0.8%

Updated

27 Jun, 2022

Data

Company Financials
NURO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NURO Stock Overview

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico.

NeuroMetrix Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NeuroMetrix
Historical stock prices
Current Share PriceUS$3.61
52 Week HighUS$38.75
52 Week LowUS$2.70
Beta2.82
1 Month Change-11.95%
3 Month Change-16.63%
1 Year Change0.84%
3 Year Change-15.83%
5 Year Change-86.58%
Change since IPO-100.00%

Recent News & Updates

May 11
We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

NUROUS Medical EquipmentUS Market
7D11.4%6.7%6.3%
1Y0.8%-24.0%-18.8%

Return vs Industry: NURO exceeded the US Medical Equipment industry which returned -23.6% over the past year.

Return vs Market: NURO exceeded the US Market which returned -18.4% over the past year.

Price Volatility

Is NURO's price volatile compared to industry and market?
NURO volatility
NURO Average Weekly Movement25.5%
Medical Equipment Industry Average Movement10.4%
Market Average Movement8.1%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: NURO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 26% a week.

Volatility Over Time: NURO's weekly volatility has decreased from 39% to 26% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199623Shai Gozanihttps://www.neurometrix.com

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons.

NeuroMetrix Fundamentals Summary

How do NeuroMetrix's earnings and revenue compare to its market cap?
NURO fundamental statistics
Market CapUS$25.29m
Earnings (TTM)-US$3.18m
Revenue (TTM)US$8.40m

3.0x

P/S Ratio

-8.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NURO income statement (TTM)
RevenueUS$8.40m
Cost of RevenueUS$2.26m
Gross ProfitUS$6.14m
Other ExpensesUS$9.32m
Earnings-US$3.18m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.45
Gross Margin73.04%
Net Profit Margin-37.86%
Debt/Equity Ratio0%

How did NURO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is NURO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NURO?

Other financial metrics that can be useful for relative valuation.

NURO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.2x
Enterprise Value/EBITDA-0.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does NURO's PS Ratio compare to its peers?

NURO PS Ratio vs Peers
The above table shows the PS ratio for NURO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average32.9x
EKSO Ekso Bionics Holdings
1.9x36.9%US$22.7m
BIOL BIOLASE
0.8x11.0%US$31.5m
TNON Tenon Medical
128.6x145.3%US$27.8m
VERO Venus Concept
0.3x19.3%US$28.8m
NURO NeuroMetrix
3xn/aUS$25.3m

Price-To-Sales vs Peers: NURO is good value based on its Price-To-Sales Ratio (3x) compared to the peer average (32.9x).


Price to Earnings Ratio vs Industry

How does NURO's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Sales vs Industry: NURO is good value based on its Price-To-Sales Ratio (3x) compared to the US Medical Equipment industry average (3.9x)


Price to Sales Ratio vs Fair Ratio

What is NURO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NURO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate NURO's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of NURO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NURO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NURO's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NURO's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is NeuroMetrix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


16.1%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NeuroMetrix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine NeuroMetrix's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has NeuroMetrix performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


57.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NURO is currently unprofitable.

Growing Profit Margin: NURO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NURO is unprofitable, but has reduced losses over the past 5 years at a rate of 57.8% per year.

Accelerating Growth: Unable to compare NURO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NURO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: NURO has a negative Return on Equity (-13.12%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is NeuroMetrix's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NURO's short term assets ($25.6M) exceed its short term liabilities ($1.7M).

Long Term Liabilities: NURO's short term assets ($25.6M) exceed its long term liabilities ($283.2K).


Debt to Equity History and Analysis

Debt Level: NURO is debt free.

Reducing Debt: NURO has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NURO has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: NURO has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 40.1% each year


Discover healthy companies

Dividend

What is NeuroMetrix current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NURO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NURO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NURO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NURO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NURO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

8.9yrs

Average management tenure


CEO

Shai Gozani (56 yo)

26yrs

Tenure

US$557,656

Compensation

Dr. Shai N. Gozani, M.D., Ph D., founded Neurometrix Inc. in 1996 and has been its President since 2002 and Chief Executive Officer since 1997 and its Secretary July 2008. He has been the Chairman of the B...


CEO Compensation Analysis

Compensation vs Market: Shai's total compensation ($USD557.66K) is about average for companies of similar size in the US market ($USD748.70K).

Compensation vs Earnings: Shai's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: NURO's management team is seasoned and experienced (8.9 years average tenure).


Board Members

Experienced Board: NURO's board of directors are seasoned and experienced ( 11.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 84.2%.


Top Shareholders

Company Information

NeuroMetrix, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: NeuroMetrix, Inc.
  • Ticker: NURO
  • Exchange: NasdaqCM
  • Founded: 1996
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$25.292m
  • Shares outstanding: 7.01m
  • Website: https://www.neurometrix.com

Number of Employees


Location

  • NeuroMetrix, Inc.
  • 4B Gill Street
  • Woburn
  • Massachusetts
  • 1801
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.